Role of excess volume in the pathophysiology of hypertension in chronic kidney disease.

BACKGROUND The pathophysiology of hypertension in patients with chronic kidney disease (CKD) is largely attributed to positive sodium balance. It is unclear how loop diuretics affect fluid volume compartments, especially with respect to their antihypertensive effect. METHODS Subjects with CKD were administered a single therapeutically equivalent dose of an oral loop diuretic (furosemide or torsemide in randomized crossover design). We measured acute volume changes over 12 hours using biophysical and hormonal biomarkers and then 24-hour ambulatory blood pressure after daily diuretic therapy for 3 weeks. RESULTS Single-dose administration of loop diuretic decreased extracellular water (ECW) by 1.7 L [95% confidence interval (95% CI) 1.2, 2.2, P < 0.001], total body water (TBW) by 1.2 L (95% CI 0.5, 1.9, P < 0.001), and increased natural log (ln) plasma renin activity (PRA) from -1.2 +/- 1.3 ng/mL/hour to -0.5 +/- 1.5 ng/mL/hour (P < 0.001). Daily loop diuretic administration resulted in reduced ECW from 24.2 +/- 6.4 L to 22.3 +/- 5.2 L (P = 0.02) and TBW from 54.3 +/- 12.7 L to 51.6 +/- 11.9 L (P < 0.001) in 1 week. After 3 weeks of diuretic therapy, whereas ECW reduction persisted at 22.8 +/- 5.1 L (P = 0.05), TBW trended toward baseline level at 52.7 +/- 11.8 L. A concomitant increase in ln PRA from -1.0 +/- 1.3 ng/mL/hour to 0.4 +/- 1.9 ng/mL/hour (P < 0.001) and ln plasma aldosterone (PA) from 2.0 +/- 0.8 ng/dL to 2.3 +/- 0.8 ng/dL (P < 0.005) and fall in ln brain natriuretic peptide (BNP) from 4.3 +/- 0.9 pg/mL to 3.7 +/- 1.0 pg/mL (P < 0.01) were seen at 1 week. Despite a trend toward restoration of TBW, changes in hormonal biomarkers were maintained at 3 weeks. Over these 3 weeks, furosemide reduced 24-hour ambulatory blood pressure from 147 +/- 17/78 +/- 11 mm Hg to 138 +/- 21/74 +/- 12 mm Hg (P = 0.021) and torsemide reduced it from 143 +/- 18/75 +/- 10 mm Hg to 133 +/- 19/71 +/- 10 mm Hg (P = 0.007). CONCLUSION Patients with CKD have elevated extracellular fluid volume that can be corrected acutely with loop diuretics. Persistent diuretic use results in dynamic changes in ECW and other body fluid compartments that translate into chronic blood pressure reduction.

[1]  C. Saha,et al.  A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. , 2003, Kidney international.

[2]  Shawn D. Chase,et al.  Liquid chromatography for iothalamate in biological samples. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[4]  J. Díez,et al.  Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Pischon,et al.  Obesity as a risk factor in renal transplant patients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  A. Protter,et al.  Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. , 1999, The Journal of pharmacology and experimental therapeutics.

[7]  J. Coresh,et al.  Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  N. Graudal,et al.  Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. , 1998, JAMA.

[9]  R. Berg,et al.  Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  Kazuhiro Takahashi,et al.  Urinary immunoreactive brain natriuretic peptide in patients with renal disease , 1996, Regulatory Peptides.

[11]  H. Inoue,et al.  Antifibrillatory Effects of Class III Antiarrhythmic Drugs: Comparative Study with Flecainide , 1993, Journal of cardiovascular pharmacology.

[12]  F. Luft.  Torasemide in the treatment of arterial hypertension. , 1993, Journal of cardiovascular pharmacology.

[13]  P Kligfield,et al.  Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. , 1992, Journal of the American College of Cardiology.

[14]  M. Zillikens,et al.  Whole-body and segmental bioelectrical-impedance analysis in patients with cirrhosis of the liver: changes after treatment of ascites. , 1992, The American journal of clinical nutrition.

[15]  D. Goeddel,et al.  Differential regional expression of three natriuretic peptide receptor genes within primate tissues , 1991, Molecular and cellular biology.

[16]  W. Forssmann,et al.  Degradation of porcine brain natriuretic peptide (pBNP-26) by endoprotease-24.11 from kidney cortical membranes. , 1989, Biochemical and biophysical research communications.

[17]  N. Spannbrucker,et al.  Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. , 1988, Arzneimittel-Forschung.

[18]  J. Roos,et al.  Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. , 1985, Hypertension.

[19]  H. Smulyan,et al.  Systolic hypertension in the elderly. Hemodynamic response to long-term thiazide diuretic therapy and its side effects. , 1983, JAMA.

[20]  J. Roos,et al.  A study on the distribution of body fluids after rapid saline expansion in normal subjects and in patients with renal insufficiency: preferential intravascular deposition in renal failure. , 1983, Clinical science.

[21]  J. Pratt.  Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. , 1982, The Journal of clinical investigation.

[22]  J. Roos,et al.  Salt Sensitivity of Blood Pressure in Chronic Renal Failure: Evidence for Renal Control of Body Fluid Distribution in Man , 1982, Hypertension.

[23]  B. Garrett,et al.  Moderate sodium restriction and various diuretics in the treatment of hypertension. , 1981, Archives of internal medicine.

[24]  M. Schalekamp,et al.  Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. , 2009, Acta medica Scandinavica.

[25]  P. G. Fernandez,et al.  Peripheral renin activity before and after furosemide in normotensives and hypertensives. , 1980, Clinical and investigative medicine. Medecine clinique et experimentale.

[26]  R. Carey,et al.  The Renin Response to Diuretic Therapy: A Limitation of Antihypertensive Potential , 1978, Circulation research.

[27]  A. Zanchetti,et al.  Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients. , 1978, Clinical science and molecular medicine. Supplement.

[28]  J. Hook,et al.  Control of Renin Secretion in the Dog: EFFECTS OF FUROSEMIDE ON THE VASCULAR AND MACULA DENSA RECEPTORS , 1975, Circulation research.

[29]  J. Joossens,et al.  Moderate sodium restriction and diuretics in the treatment of hypertension. , 1973, American heart journal.

[30]  A. Leth.  Changes in Plasma and Extracellular Fluid Volumes in Patients with Essential Hypertension During Long‐Term Treatment with Hydrochlorothiazide , 1970, Circulation.

[31]  B. Winer.  The Antihypertensive Mechanisms of Salt Depletion Induced by Hydrochlorothiazide , 1961, Circulation.

[32]  J. Conway,et al.  Hemodynamic and Hypotensive Effects of Long‐term Therapy with Chlorothiazide , 1960, Circulation.

[33]  E. Freis,et al.  Relationship Between Plasma and Extracellular Fluid Volume Depletion and the Antihypertensive Effect of Chlorothiazide , 1959, Circulation.

[34]  J. Gajewski,et al.  Influence of chlorothiazide upon arterial responsiveness to nor-epinephrine in hypertensive subjects. , 1959, The New England journal of medicine.